Andreas Thiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Thiel has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
Beate Kruse
Si‐M/“Der Simulierte Mensch” a science framework of Technische Universität Berlin and Charité ‐ Universitätsmedizin Berlin Berlin Germany
11 shared publicationsJulian Braun
Si‐M/“Der Simulierte Mensch” a science framework of Technische Universität Berlin and Charité ‐ Universitätsmedizin Berlin Berlin Germany
10 shared publications- Lucie Loyal
Der Simulierte Mensch, Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
10 shared publications Manuela Dingeldey
Si‐M/“Der Simulierte Mensch” a science framework of Technische Universität Berlin and Charité ‐ Universitätsmedizin Berlin Berlin Germany
9 shared publicationsMarco Frentsch
Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin Charité—Universitätsmedizin Berlin Berlin Germany
9 shared publicationsAndreas Radbruch
Cellular Biology, German Rheumatism Research Center (DRFZ), Institute of the Leibniz Association, Berlin, Germany
8 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (3)
Arming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation
- 14 July 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (3)
Open AccessArming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation
- Open Access
- 11 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Histamine-induced RPS6 phosphorylation in dendritic cells is associated with the severity of peanut allergic reactions
The phosphorylation of the ribosomal protein S6 (RPS6) was reported to be increased in myeloid cell subsets after stimulation with peanut extract in peanut-allergic individuals or with anti-IgE antibodies in both allergic and nonallergic donors. The mechanisms driving this increase of RPS6 phosphorylation (pS6) and its clinical impacts remain to be elucidated. Therefore, we investigated the mechanism of pS6 induction in plasmacytoid DCs (pDCs) and conventional DCs (cDCs) using whole blood stimulated with peanut extract or anti-IgE antibodies. This approach included in vitro basophil depletion and the application of receptor antagonists. Clinical associations with differential pS6 were performed with data from a well-defined cohort of peanut-allergic individuals participating in the food intervention trial TINA. Our findings revealed an increase of pS6 in pDCs and cDCs via histamine receptor 2 (H2R) signaling after IgE-dependent basophil degranulation and histamine release. In adults — but not in children — pS6 in cDCs was positively associated with food allergy severity, as determined by titrated oral food challenges. The association of pS6 in cDCs with food allergy severity in an age-dependent manner suggests a possibly novel functional mechanism, which may contribute to the course of food allergy, e.g., via increased antigen presentation.
- 11 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Open AccessHistamine-induced RPS6 phosphorylation in dendritic cells is associated with the severity of peanut allergic reactions
The phosphorylation of the ribosomal protein S6 (RPS6) was reported to be increased in myeloid cell subsets after stimulation with peanut extract in peanut-allergic individuals or with anti-IgE antibodies in both allergic and nonallergic donors. The mechanisms driving this increase of RPS6 phosphorylation (pS6) and its clinical impacts remain to be elucidated. Therefore, we investigated the mechanism of pS6 induction in plasmacytoid DCs (pDCs) and conventional DCs (cDCs) using whole blood stimulated with peanut extract or anti-IgE antibodies. This approach included in vitro basophil depletion and the application of receptor antagonists. Clinical associations with differential pS6 were performed with data from a well-defined cohort of peanut-allergic individuals participating in the food intervention trial TINA. Our findings revealed an increase of pS6 in pDCs and cDCs via histamine receptor 2 (H2R) signaling after IgE-dependent basophil degranulation and histamine release. In adults — but not in children — pS6 in cDCs was positively associated with food allergy severity, as determined by titrated oral food challenges. The association of pS6 in cDCs with food allergy severity in an age-dependent manner suggests a possibly novel functional mechanism, which may contribute to the course of food allergy, e.g., via increased antigen presentation.
- Open Access
- 28 July 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (7) , e51888
Aging and Viral Evolution Impair Immunity Against Dominant Pan‐Coronavirus‐Reactive T Cell Epitope
Immune evasion by escape mutations subverts immunity against SARS‐CoV‐2. A role of pan‐coronavirus immunity for more durable protection is being discussed, but has remained understudied. We here investigated the effects of age, mutations, and homo‐/heterologous vaccination regimens on the dominant pan‐coronavirus‐specific cellular and humoral epitope iCope after SARS‐CoV‐2 infection and vaccination in detail. In older individuals, the quantitatively and qualitatively reduced iCope‐reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast, pan‐coronavirus‐reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan‐coronavirus immunity in the older, critical for long‐term protection against SARS‐CoV‐2 variants.
- 28 July 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (7) , e51888
Open AccessAging and Viral Evolution Impair Immunity Against Dominant Pan‐Coronavirus‐Reactive T Cell Epitope
Immune evasion by escape mutations subverts immunity against SARS‐CoV‐2. A role of pan‐coronavirus immunity for more durable protection is being discussed, but has remained understudied. We here investigated the effects of age, mutations, and homo‐/heterologous vaccination regimens on the dominant pan‐coronavirus‐specific cellular and humoral epitope iCope after SARS‐CoV‐2 infection and vaccination in detail. In older individuals, the quantitatively and qualitatively reduced iCope‐reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast, pan‐coronavirus‐reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan‐coronavirus immunity in the older, critical for long‐term protection against SARS‐CoV‐2 variants.
- Open Access
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadr9331
CD8 + T cell–derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells
T cells and their effector functions, in particular the canonical cytotoxicity of CD8 + T cells involving perforin, granzymes, Fas ligand (FasL), and tumor necrosis factor related apoptosis inducing ligand (TRAIL), are crucial for tumor immunity. Here, we reveal a previously unidentified mechanism by which CD40L-expressing CD8 + T cells induce cytotoxicity in cancer cells. In murine models, up to 50% of tumor-specific CD8 + T cells expressed CD40L, and conditional CD40L ablation in CD8 + T cells alone led to tumor formation. Mechanistically, CD40L + CD8 + T cells can induce cell death in CD40-expressing cancer cells by triggering caspase-8 activation. We demonstrate that a gene signature for resistance to CD40 signaling–induced cell death strongly correlates with worse survival in different human cancer cohorts. Our results introduce CD40L as a rather counterintuitive, noncanonical cytotoxic factor that complements the capabilities of CD8 + T cells to combat cancers and has the potential to enhance the efficacy of immunotherapies.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadr9331
Open AccessCD8 + T cell–derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells
T cells and their effector functions, in particular the canonical cytotoxicity of CD8 + T cells involving perforin, granzymes, Fas ligand (FasL), and tumor necrosis factor related apoptosis inducing ligand (TRAIL), are crucial for tumor immunity. Here, we reveal a previously unidentified mechanism by which CD40L-expressing CD8 + T cells induce cytotoxicity in cancer cells. In murine models, up to 50% of tumor-specific CD8 + T cells expressed CD40L, and conditional CD40L ablation in CD8 + T cells alone led to tumor formation. Mechanistically, CD40L + CD8 + T cells can induce cell death in CD40-expressing cancer cells by triggering caspase-8 activation. We demonstrate that a gene signature for resistance to CD40 signaling–induced cell death strongly correlates with worse survival in different human cancer cohorts. Our results introduce CD40L as a rather counterintuitive, noncanonical cytotoxic factor that complements the capabilities of CD8 + T cells to combat cancers and has the potential to enhance the efficacy of immunotherapies.
- Open Access
- 16 February 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (2) , 115314
Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly
- 16 February 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (2) , 115314
Open AccessHybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly
- Open Access
Aging and viral evolution impair immunity against dominant pan-coronavirus-reactive T cell epitope
Immune evasion by escape mutations subverts immunity against SARS-CoV-2. A role of pan-coronavirus immunity for more durable protection is being discussed but has remained understudied. We here investigated the effects of age, mutations, and homo-/heterologous vaccination regimens on the dominant pan-coronavirus-specific cellular and humoral epitope iCope after SARS-CoV-2 infection and vaccination in detail. In the older, quantitatively, and qualitatively reduced iCope-reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast pan-coronavirus-reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan-coronavirus immunity in the older, critical for long-term protection against SARS-CoV-2 variants. One-Sentence Summary: Aging and viral evolution impair dominant pan-coronavirus immunity, a hallmark of efficient and broad immune competence against SARS-CoV-2
Open AccessAging and viral evolution impair immunity against dominant pan-coronavirus-reactive T cell epitope
Immune evasion by escape mutations subverts immunity against SARS-CoV-2. A role of pan-coronavirus immunity for more durable protection is being discussed but has remained understudied. We here investigated the effects of age, mutations, and homo-/heterologous vaccination regimens on the dominant pan-coronavirus-specific cellular and humoral epitope iCope after SARS-CoV-2 infection and vaccination in detail. In the older, quantitatively, and qualitatively reduced iCope-reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast pan-coronavirus-reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan-coronavirus immunity in the older, critical for long-term protection against SARS-CoV-2 variants. One-Sentence Summary: Aging and viral evolution impair dominant pan-coronavirus immunity, a hallmark of efficient and broad immune competence against SARS-CoV-2
- Open Access
- 22 March 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (3) , e29539
Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination responses in healthy individuals, there is comparatively little known beyond antibody titers and T‐cell responses in the vulnerable cohort of patients after allogeneic hematopoietic stem cell transplantation (ASCT). In this study, we assessed the serological response and performed longitudinal multimodal analyses including T‐cell functionality and single‐cell RNA sequencing combined with T cell receptor (TCR)/B cell receptor (BCR) profiling in the context of BNT162b2 vaccination in ASCT patients. In addition, these data were compared to publicly available data sets of healthy vaccinees. Protective antibody titers were achieved in 40% of patients. We identified a distorted B‐ and T‐cell distribution, a reduced TCR diversity, and increased levels of exhaustion marker expression as possible causes for the poorer vaccine response rates in ASCT patients. Immunoglobulin heavy chain gene rearrangement after vaccination proved to be highly variable in ASCT patients. Changes in TCRα and TCRβ gene rearrangement after vaccination differed from patterns observed in healthy vaccinees. Crucially, ASCT patients elicited comparable proportions of SARS‐CoV‐2 vaccine‐induced (VI) CD8+ T‐cells, characterized by a distinct gene expression pattern that is associated with SARS‐CoV‐2 specificity in healthy individuals. Our study underlines the impaired immune system and thus the lower vaccine response rates in ASCT patients. However, since protective vaccine responses and VI CD8+ T‐cells can be induced in part of ASCT patients, our data advocate early posttransplant vaccination due to the high risk of infection in this vulnerable group.
- 22 March 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (3) , e29539
Open AccessComparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination responses in healthy individuals, there is comparatively little known beyond antibody titers and T‐cell responses in the vulnerable cohort of patients after allogeneic hematopoietic stem cell transplantation (ASCT). In this study, we assessed the serological response and performed longitudinal multimodal analyses including T‐cell functionality and single‐cell RNA sequencing combined with T cell receptor (TCR)/B cell receptor (BCR) profiling in the context of BNT162b2 vaccination in ASCT patients. In addition, these data were compared to publicly available data sets of healthy vaccinees. Protective antibody titers were achieved in 40% of patients. We identified a distorted B‐ and T‐cell distribution, a reduced TCR diversity, and increased levels of exhaustion marker expression as possible causes for the poorer vaccine response rates in ASCT patients. Immunoglobulin heavy chain gene rearrangement after vaccination proved to be highly variable in ASCT patients. Changes in TCRα and TCRβ gene rearrangement after vaccination differed from patterns observed in healthy vaccinees. Crucially, ASCT patients elicited comparable proportions of SARS‐CoV‐2 vaccine‐induced (VI) CD8+ T‐cells, characterized by a distinct gene expression pattern that is associated with SARS‐CoV‐2 specificity in healthy individuals. Our study underlines the impaired immune system and thus the lower vaccine response rates in ASCT patients. However, since protective vaccine responses and VI CD8+ T‐cells can be induced in part of ASCT patients, our data advocate early posttransplant vaccination due to the high risk of infection in this vulnerable group.
- Open Access
- 25 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64+HLADRlow granulocytes, showed significant correlations with B and T cell responses induced by vaccination. Our findings suggest the potential role of myeloid cells in cellular and humoral responses following vaccination in DMT-treated patients with neuroimmunological diseases.
- 25 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessAssociations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64+HLADRlow granulocytes, showed significant correlations with B and T cell responses induced by vaccination. Our findings suggest the potential role of myeloid cells in cellular and humoral responses following vaccination in DMT-treated patients with neuroimmunological diseases.
- Open Access
- 31 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1056525
Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines. All of them contain the spike glycoprotein as the main immunogen and result in reduced disease severity upon SARS-CoV-2 infection. While we and others have shown that mRNA-based vaccination reactivates pre-existing, cross-reactive immunity, the effect of vector vaccines in this regard is unknown. Here, we studied cellular and humoral responses in heterologous adenovirus-vector-based ChAdOx1 nCOV-19 (AZ; Vaxzeria, AstraZeneca) and mRNA-based BNT162b2 (BNT; Comirnaty, BioNTech/Pfizer) vaccination and compared it to a homologous BNT vaccination regimen. AZ primary vaccination did not lead to measurable reactivation of cross-reactive cellular and humoral immunity compared to BNT primary vaccination. Moreover, humoral immunity induced by primary vaccination with AZ displayed differences in linear spike peptide epitope coverage and a lack of anti-S2 IgG antibodies. Contrary to primary AZ vaccination, secondary vaccination with BNT reactivated pre-existing, cross-reactive immunity, comparable to homologous primary and secondary mRNA vaccination. While induced anti-S1 IgG antibody titers were higher after heterologous vaccination, induced CD4+ T cell responses were highest in homologous vaccinated. However, the overall TCR repertoire breadth was comparable between heterologous AZ-BNT-vaccinated and homologous BNT-BNT-vaccinated individuals, matching TCR repertoire breadths after SARS-CoV-2 infection, too. The reasons why AZ and BNT primary vaccination elicits different immune response patterns to essentially the same antigen, and the associated benefits and risks, need further investigation to inform vaccine and vaccination schedule development.
- 31 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1056525
Open AccessPrimary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines. All of them contain the spike glycoprotein as the main immunogen and result in reduced disease severity upon SARS-CoV-2 infection. While we and others have shown that mRNA-based vaccination reactivates pre-existing, cross-reactive immunity, the effect of vector vaccines in this regard is unknown. Here, we studied cellular and humoral responses in heterologous adenovirus-vector-based ChAdOx1 nCOV-19 (AZ; Vaxzeria, AstraZeneca) and mRNA-based BNT162b2 (BNT; Comirnaty, BioNTech/Pfizer) vaccination and compared it to a homologous BNT vaccination regimen. AZ primary vaccination did not lead to measurable reactivation of cross-reactive cellular and humoral immunity compared to BNT primary vaccination. Moreover, humoral immunity induced by primary vaccination with AZ displayed differences in linear spike peptide epitope coverage and a lack of anti-S2 IgG antibodies. Contrary to primary AZ vaccination, secondary vaccination with BNT reactivated pre-existing, cross-reactive immunity, comparable to homologous primary and secondary mRNA vaccination. While induced anti-S1 IgG antibody titers were higher after heterologous vaccination, induced CD4+ T cell responses were highest in homologous vaccinated. However, the overall TCR repertoire breadth was comparable between heterologous AZ-BNT-vaccinated and homologous BNT-BNT-vaccinated individuals, matching TCR repertoire breadths after SARS-CoV-2 infection, too. The reasons why AZ and BNT primary vaccination elicits different immune response patterns to essentially the same antigen, and the associated benefits and risks, need further investigation to inform vaccine and vaccination schedule development.
- Open Access
- 5 October 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (10) , e12197
An interdisciplinary approach to characterize peanut‐allergic patients—First data from the FOOD@ consortium
Background: Peanut allergy is a frequent cause of food allergy and potentially life‐threatening. Within this interdisciplinary research approach, we aim to unravel the complex mechanisms of peanut allergy. As a first step were applied in an exploratory manner the analysis of peanut allergic versus non‐allergic controls.Methods: Biosamples were studied regarding DNA methylation signatures, gut microbiome, adaptive and innate immune cell populations, soluble signaling molecules and allergen‐reactive antibody specificities. We applied a scalable systems medicine computational workflow to the assembled data.Results: We identified combined cellular and soluble biomarker signatures that stratify donors into peanut‐allergic and non‐allergic with high specificity. DNA methylation profiling revealed various genes of interest and stool microbiota differences in bacteria abundances.Conclusion: By extending our findings to a larger set of patients (e.g., children vs. adults), we will establish predictors for food allergy and tolerance and translate these as for example, indicators for interventional studies.
- 5 October 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (10) , e12197
Open AccessAn interdisciplinary approach to characterize peanut‐allergic patients—First data from the FOOD@ consortium
Background: Peanut allergy is a frequent cause of food allergy and potentially life‐threatening. Within this interdisciplinary research approach, we aim to unravel the complex mechanisms of peanut allergy. As a first step were applied in an exploratory manner the analysis of peanut allergic versus non‐allergic controls.Methods: Biosamples were studied regarding DNA methylation signatures, gut microbiome, adaptive and innate immune cell populations, soluble signaling molecules and allergen‐reactive antibody specificities. We applied a scalable systems medicine computational workflow to the assembled data.Results: We identified combined cellular and soluble biomarker signatures that stratify donors into peanut‐allergic and non‐allergic with high specificity. DNA methylation profiling revealed various genes of interest and stool microbiota differences in bacteria abundances.Conclusion: By extending our findings to a larger set of patients (e.g., children vs. adults), we will establish predictors for food allergy and tolerance and translate these as for example, indicators for interventional studies.